0001193125-22-105004.txt : 20220414 0001193125-22-105004.hdr.sgml : 20220414 20220414083431 ACCESSION NUMBER: 0001193125-22-105004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220414 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 22826087 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d343288d8k.htm 8-K 8-K
false 0001690585 0001690585 2022-04-14 2022-04-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2022

 

 

MAGENTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38541   81-0724163

(State or other jurisdiction

of incorporation)

   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

100 Technology Square

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (857) 242-0170

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 Par Value   MGTA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

On April 14, 2022, Magenta Therapeutics, Inc. issued a press release regarding certain corporate and clinical updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:

 

99.1    Press Release dated April 14, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MAGENTA THERAPEUTICS, INC.
Date:   April 14, 2022
By:  

/s/ Stephen Mahoney

  Stephen Mahoney
Title:   Chief Financial and Operating Officer

 

3

EX-99.1 2 d343288dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends

Cash Runway

– Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial –

– Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 –

CAMBRIDGE, Mass. – April 14, 2022 – Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its MGTA-117 Phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug conjugate) IND-enabling activities and the MGTA-145 stem cell mobilization efforts in sickle cell disease.

The Company’s most significant near-term clinical milestone is its anticipated data from the MGTA-117 Phase 1/2 clinical trial in patients with relapsed/refractory acute myeloid leukemia and myelodysplasia-excess blasts. Multiple patients have been dosed in Cohort 1 of the ongoing clinical trial. Based on a preliminary review of the data from the trial to date, Magenta believes that the data suggest early signals of positive pharmacodynamic activity and that MGTA-117 has been well-tolerated, with no reports of unexpected or significant drug-related adverse events. Magenta looks forward to translating data from this clinical trial for use in transplant-eligible patients in the future. In its Q1 2022 earnings release scheduled for early May 2022, Magenta plans to disclose a summary of clinical observations from these initial patients with respect to CD117 target binding, drug clearance, cell depletion and tolerability.

Due to both its early positive experience with the MGTA-117 clinical trial and in response to the uncertain capital market environment for biotechnology companies, Magenta recognizes the need for an increased focus on MGTA-117 while also de-prioritizing other portfolio investments. The revised operating plan includes reductions in spending related to general and administrative expenses and research platform-related investments in new disease targets, as well as pausing certain MGTA-145 investments, including the program’s planned MGTA-145 dosing and administration optimization clinical trial in healthy subjects.

Magenta’s revised operating plan also reduces the Company’s workforce by 14% and allows Magenta to extend its cash runway into Q2 2024.

“We are encouraged by our progress in the MGTA-117 clinical trial and want to proactively address our resource allocation to ensure focus on creating value for patients and all of our stakeholders,” said Jason Gardner, President and Chief Executive Officer of Magenta Therapeutics. “We have the utmost respect and appreciation for our departing employees and their contribution to advancing our programs.”

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize immune and blood reset to allow more patients to take advantage of the curative potential of stem cell transplant as well as potentially improve eligibility for future gene therapies.

Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. These statements include, without limitation, implied and express statements relating to: Magenta’s future business expectations, plans and prospects; the prioritization of Magenta’s operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug conjugate) IND-enabling activities and the MGTA-145 stem cell mobilization efforts in sickle cell disease; the potential of, and expectations for, Magenta’s product candidate pipeline; the potential benefits and expected performance of Magenta’s product candidates and programs; the development of Magenta’s product candidates and advancement of Magenta’s preclinical and clinical programs; expectations, plans and timing for preclinical activities and clinical trials involving Magenta’s product candidates; expectations, plans and timing for the receipt and disclosure of preclinical and clinical data, and other results involving Magenta’s product candidates; timelines and expectations for patient dosing, dosing regimens and administration; translating data from the MGTA-117 Phase 1/2 clinical trial in patients with relapsed/refractory acute myeloid leukemia and myelodysplasia-excess blasts for use in the transplant-eligible patients in the future; the anticipated benefits of Magenta’s revised operating plan; and Magenta’s expectation

that its cash runway will extend into the second quarter of 2024. Words such as “anticipate,” “believe,” “continue,” “could,” “designed,” “endeavor,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: volatility and uncertainty in the capital markets for biotechnology companies; uncertainties inherent in preclinical and clinical trials, and in the availability and timing of data from ongoing and planned clinical and preclinical trials; the ability to initiate, enroll, conduct or complete ongoing and planned preclinical and clinical trials; vulnerability and/or fragility of, and the presence of underlying disorders in, the patient population for the clinical trials of Magenta’s product candidates, including the MGTA-117 Phase 1/2 clinical trial in patients with relapsed/refractory acute myeloid leukemia and myelodysplasia-excess blasts; the delay of any current or planned preclinical or clinical trials or the development of Magenta’s product candidates; whether results from preclinical or earlier clinical trials will be predictive of the results of future trials; interactions with regulatory agencies such as the U.S. Food and Drug Administration; the expected timing of submissions for regulatory approval to conduct or continue trials or to market products; Magenta’s ability to successfully demonstrate the safety and efficacy of its product candidates; whether Magenta’s cash resources will be sufficient to fund Magenta’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; and risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Magenta’s business, operations, preclinical activities, clinical trials, strategy, goals and anticipated timelines. These and other risks are described in additional detail in Magenta’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 8, 2022, and its other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release represent Magenta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Magenta explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

Contact:

Jill Bertotti, Real Chemistry (advisor to Magenta)

714-225-6726

jbertotti@realchemistry.com

EX-101.SCH 3 mgta-20220414.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mgta-20220414_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 mgta-20220414_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g343288img1.jpg GRAPHIC begin 644 g343288img1.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 14, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001690585
Document Type 8-K
Document Period End Date Apr. 14, 2022
Entity Registrant Name MAGENTA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38541
Entity Tax Identification Number 81-0724163
Entity Address, Address Line One 100 Technology Square
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (857)
Local Phone Number 242-0170
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 Par Value
Trading Symbol MGTA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false

XML 8 d343288d8k_htm.xml IDEA: XBRL DOCUMENT 0001690585 2022-04-14 2022-04-14 false 0001690585 8-K 2022-04-14 MAGENTA THERAPEUTICS, INC. DE 001-38541 81-0724163 100 Technology Square Cambridge MA 02139 (857) 242-0170 false false false false Common Stock, $0.001 Par Value MGTA NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d343288d8k.htm d343288dex991.htm mgta-20220414.xsd mgta-20220414_lab.xml mgta-20220414_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d343288d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d343288d8k.htm" ] }, "labelLink": { "local": [ "mgta-20220414_lab.xml" ] }, "presentationLink": { "local": [ "mgta-20220414_pre.xml" ] }, "schema": { "local": [ "mgta-20220414.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mgta", "nsuri": "http://www.magentatx.com/20220414", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d343288d8k.htm", "contextRef": "duration_2022-04-14_to_2022-04-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d343288d8k.htm", "contextRef": "duration_2022-04-14_to_2022-04-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.magentatx.com//20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-105004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-105004-xbrl.zip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